These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29562252)

  • 21. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
    Sfikakis PP; Boletis JN; Tsokos GC
    Curr Opin Rheumatol; 2005 Sep; 17(5):550-7. PubMed ID: 16093832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
    Kumar S; Benseler SM; Kirby-Allen M; Silverman ED
    Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Case Report: Ofatumumab treatment in a patient with rituximab-intolerant refractory autoimmune GFAP astrocytopathy.
    Cao S; Du J; Pan S; Zhang J; Xu S; Wei L; Tian Y
    Front Immunol; 2023; 14():1164181. PubMed ID: 37223100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Progress in B-cell targeting therapy for the treatment of systemic lupus erythematosus].
    Tanaka Y
    J UOEH; 2011 Jun; 33(2):173-81. PubMed ID: 21702122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
    Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
    Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
    Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
    Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ofatumumab treatment in lupus nephritis patients.
    Haarhaus ML; Svenungsson E; Gunnarsson I
    Clin Kidney J; 2016 Aug; 9(4):552-5. PubMed ID: 27478595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
    Cheson BD
    J Clin Oncol; 2010 Jul; 28(21):3525-30. PubMed ID: 20458041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab therapy for childhood-onset systemic lupus erythematosus.
    Willems M; Haddad E; Niaudet P; Koné-Paut I; Bensman A; Cochat P; Deschênes G; Fakhouri F; Leblanc T; Llanas B; Loirat C; Pillet P; Ranchin B; Salomon R; Ulinski T; Bader-Meunier B;
    J Pediatr; 2006 May; 148(5):623-627. PubMed ID: 16737873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.
    Barth MJ; Czuczman MS
    Future Oncol; 2013 Dec; 9(12):1829-39. PubMed ID: 24295413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B-cell-targeted therapy for systemic lupus erythematosus: an update.
    Ding C; Foote S; Jones G
    BioDrugs; 2008; 22(4):239-49. PubMed ID: 18611066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment.
    Du FH; Mills EA; Mao-Draayer Y
    Auto Immun Highlights; 2017 Nov; 8(1):12. PubMed ID: 29143151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus.
    Tanaka Y; Yamamoto K; Takeuchi T; Nishimoto N; Miyasaka N; Sumida T; Shima Y; Takada K; Matsumoto I; Saito K; Koike T
    Mod Rheumatol; 2007; 17(3):191-7. PubMed ID: 17564773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of rituximab on resistant SLE disease including lung involvement.
    Reynolds JA; Toescu V; Yee CS; Prabu A; Situnayake D; Gordon C
    Lupus; 2009 Jan; 18(1):67-73. PubMed ID: 19074171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
    Robak T; Robak E
    BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment.
    Roccatello D; Sciascia S; Baldovino S; Rossi D; Alpa M; Naretto C; Di Simone D; Simoncini M; Menegatti E
    Autoimmun Rev; 2015 Dec; 14(12):1123-30. PubMed ID: 26244817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
    Tokunaga M; Fujii K; Saito K; Nakayamada S; Tsujimura S; Nawata M; Tanaka Y
    Rheumatology (Oxford); 2005 Feb; 44(2):176-82. PubMed ID: 15494350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series.
    Gualtierotti R; Borghi MO; Gerosa M; Schioppo T; Larghi P; Geginat J; Meroni PL
    Clin Exp Rheumatol; 2018; 36(4):643-647. PubMed ID: 29533753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report.
    Edelbauer M; Jungraithmayr T; Zimmerhackl LB
    Pediatr Nephrol; 2005 Jun; 20(6):811-3. PubMed ID: 15772840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.